The Global Blood Industry
The global market for blood products reached $23.5 billion in 2012. The market is expected to reach $28.8 billion in 2017 for a compound annual growth rate (CAGR) of 4.1%.
- An overview of the structure and current market size of the global blood industry, including coverage of such segments as blood and plasma collection, blood and plasma processing, blood therapeutic products, plasma therapeutic products, and emerging trends and products
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Blood usage patterns and trends
- Government and regulatory controls
- The impact of diseases on the blood industry
- Current product lines and examination of newly emerging products and technologies
- Newly issued patents relating to blood therapeutics, processing, screening, and collection technologies
- Comprehensive company profiles of major players in the industry.
SCOPE AND FORMAT
This study encompasses the wide range of products and services that comprise the global blood industry marketplace. The U.S. market, the largest in the world, provides the primary market breakdown with supplemental information given for other select regions. The focus of the report is two-fold: first, blood for donation and the components and derived products from this blood and plasma, and second, products used to provide and support collection, processing and transfusion. Excluded from consideration are the clinical blood tests for diseases and conditions not involved in managing blood and plasma products.
MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.
The global blood market includes products used for collecting, typing, processing, and transfusing of blood and the sale of blood therapeutics. This market was worth $30 billion in 2010 and is forecast to increase at an 8.4% compound annual growth rate (CAGR) to reach $45 billion in 2015.
- The U.S. blood market was worth $7.8 billion in 2007. It should reach $9.5 million by 2012, a compound annual growth rate (CAGR) of 5.7%.
- Products used for collecting, processing and transfusing blood will grow from a $1.6 billion segment in 2007 to $2.2 billion by the end of the study period.
- Major driving forces in the industry include the cost of collection and processing, and changes in the incidences of catastrophes requiring blood transfusions.
Sales for the blood and blood components segment and the plasma derived segment of the U.S. blood market will approach $6.6 billion in 2005 and are expected to approach $9.9 billion in 2010, rising at an average annual growth rate (AAGR) of 8.5%.
The collection and processing products segment will grow from over $1.8 billion to nearly $2.5 billion at an AAGR of 7%.
The driving forces of the industry are collection and processing cost, technology, an aging population and the changes in the incidence of diseases, surgical procedures and catastrophes that require transfusions.
Safety of the blood supply is the primary issue and donation testing has been enhanced with the greater use of nuclear amplifications testing methods.
The U.S. market for products used in the blood business are expected to exceed $6.1 billion in 2001.
The market is projected to reach nearly $8.7 billion by 2006, growing at an average annual rate (AAGR) of 7.2%.
The largest segment, blood components and plasma products, makes up over 80% of the market. Growing at an AAGR of 7.8% through 2005, these products will rise to command nearly 84% of the total market.
Equipment, blood tests and additional consumables will grow at an AAGR of 4.3% from $1.2 billion in 2001 to over $1.4 billion in 2006.